Pharma

Your Article Summary

See Latest Articles

Pandemic 2009 Influenza Update: Results from second clinical trial of GSKs H1N1 adjuvanted vaccine confirm immune response and tolerability
GlaxoSmithKline, 10/19/09

GlaxoSmithKline announced results from a second clinical trial of its pandemic adjuvanted vaccine, which demonstrate that one dose of the vaccine can provide a strong immune response which exceeds criteria as defined by international licensing authorities using the lowest dose of antigen available in pandemic vaccines. The data from GSK's H1N1 trials announced to date demonstrate the vaccine is generally well tolerated.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
Cephalon, 11/24/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

 See all of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Innovative polyurethane spray systems for district cooling
BayNews International, 11/24/09

Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09

Prodesse's ProFlu-ST Assay Receives European CE Mark
Gen-Probe, 11/24/09

 See all of Research & Development